Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II savolitinib in papillary renal cell carcinoma
2014-001858-41Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of savolitinib in papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Dec 2014; status: completed.
02
Drugs
savolitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on 2014-001858-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001858-41.